解剖病理市场Share, Size, Trends, Industry Analysis Report, By Product; By Application (Disease Diagnosis, Drug Discovery and Development, Others); By End-Use (Hospitals, Research Laboratories, Diagnostic Laboratories, Others), By Region; Segment Forecast, 2022 - 2030
- 发布日期：2月2022年
- 页数：112
- Format: PDF
- Report ID: PM2253
- Base Year: 2021
- Historical Data: 2018 - 2020
报告摘要
2021年全球解剖病理学市场的价值为352.1亿美元，预计预测期内的复合年增长率为7.3％。癌症和其他靶疾病的高发病率，报销可用性，癌症筛查的建议以及对个性化护理的增加均推动全球解剖病理市场的增长。
了解有关此报告的更多信息:请求样本页面
Moreover, emerging economies such as India, China, and Brazil are expected to provide considerable potential possibilities for participants in the global market of anatomic pathology throughout the projected period. Anatomic determine the cause and diagnosis of organ tissues infected by disease-causing microorganisms in order to understand how syndrome affects the structure of human organs, both microscopically and holistically. The approach is frequently used to detect and treat various cancer and tumors. It can also help assess other chronic disorders such as severe infections, liver diseases, autoimmune diseases, and others.
行业动态
成长司机
The geriatric population is rapidly growing, as is the incidence rate of cancer and other chronic disorders. Cancer is the world's second-leading cause of death. As per National Cancer Institute, in the U.S., an average of 1,806,590 new cancer cases have been reported in 2020, with 606,520 people dying from the disease.
同样，根据欧洲的医学肿瘤学会，欧盟和欧洲风情会议国家的新癌症病例的数量预计将在2020年至2040年之间升高21.4％，从2020年的280万到20世纪40年增加到340万。预期癌症死亡在同期增加32.2％，从2020年的130万到2040年的130万，这反过来预计会在预测期间提高解剖病理学市场。
报告细分
该市场主要根据产品，申请，最终用途和地区分段。
By Product |
By Application |
By End-Use |
按地区 |
|
|
|
|
了解有关此报告的更多信息:请求样本页面
产品洞察力
在2021年的XX％左右的市场份额，消耗品部门占据了解剖病理市场。该部分的扩张是通过各种商品的可用性和高度消耗利用率的推动来推动。病理消耗品的低成本和方便的可用性鼓励了分部的增长，提高了解剖病理市场增长。
ISH iVIEW Blue Plus; and Instrument Cleaning Kit are some of the most important reagents and kits. Furthermore, the substantial share of this category can be linked to the availability of diagnostic test reimbursements, rapid growth in the geriatric population, and rising cancer and other chronic illness incidences. On the contrary, the instruments segment is further expected to increase due to ongoing technological improvements and ongoing efforts by anatomic pathology market competitors to produce anatomic pathological instruments with superior designs.
Insight by Application
In 2021, the disease diagnosis category had a major market share of over XX percent. Pathology protocols allow researchers to investigate the origin of diseases and their consequences. As a result, anatomic pathology is increasingly being used in illness diagnosis on the market.
解剖病理过程有助于在炎症和生长的基质细胞阶段发现肿瘤，降低肿瘤根除成本。此外，由于制造商增加了对推出创造性和革命性诊断技术的重点，分部的增长加速了。癌症等慢性疾病的流行率和不断增长的老年人口正在推动疾病诊断部门，提高解剖病理学行业。
地理概述
North America accounted for the greatest revenue share in 2021 in the anatomic pathology industry due to the presence of major players and favorable government initiatives connected to pathological training programs. Further, the rising healthcare expenditures, favorable reimbursement scenarios for diagnostic tests, and government initiatives for cancer screening in the region are all major factors driving the region's growth.
Asia-Pacific is expected to grow at a significant CAGR of XX percent over the analyzed period, owing to an increase in the senior population base and the incidence of chronic diseases across the areas. For instance: according to AgeingAsia.org, the number of populations aged 60 and above was 11,988,000 in 2019 and is expected to rise by 29,841,000 in 2050. Also, the total percentage of the population aged 60 and above was 12.3% in 2019 and is expected to increase by 27.2 % in 2050.
竞争洞察力
Abcam plc, Agilent Technologies, Amos Scientific Pty Ltd., Beckton, Bio SB, BioGenex, Bright Instruments, Cardinal Health, Cell Signaling Technology, Inc., CellPath Ltd., Danaher Corporation, Diapath S.p.A, Dickson and Company, F. Hoffmann-La Roche AG, Histo-Line Laboratories, Hologic, Inc., Jinhua Yidi Medical Equipment Co., Ltd., Laboratory Corporation of America Holdings, Lupetec, Medimeas, MEDITE Medical GmbH, Merck KGaA, MICROS AUSTRIA, Milestone Medical, NeoGenomics Laboratories, Inc., PHC Holdings Corporation, Quest Diagnostics Incorporated, R. K. SCIENTIFIC INSTRUMENT PRIVATE LIMITED, Sakura Finetek, Sakura Finetek USA, Inc., and SLEE medical GmbH are some of the major market players operating in the anatomic pathology market.
解剖病理市场Report Scope
报告属性 |
Details |
Market size value in 2021 |
352.1亿美元 |
2030年收入预测 |
售价65.54百万美元 |
CANG. |
从2022 - 2030年7分7.3％ |
基准 |
2021. |
历史数据 |
2018年 - 2020年 |
Forecast period |
2022 - 2030年 |
定量单位 |
收入超过百万美元和2022年至2030美元的CAGR |
持续的段 |
By Product, By Application, By End-Use, By By Region |
区域范围 |
北美，欧洲，亚太地区，拉丁美洲，中东和非洲 |
主要公司 |
Amos Scientific Pty Ltd.,Beckton,Bio SB,BioGenex,明亮的乐器,红衣主教健康,Cell Signaling Technology，Inc。,CellPath Ltd.,丹纳赫公司,履行S.P.A.,迪克森和公司,F. Hoffmann-La Roche AG,Histo-Line Laboratories,HOLOGIC，INC。,金华怡迪医疗设备有限公司,美国实验室公司控股,lupetec.,medimeas.,Medite Medical GmbH.,默克kgaa.,微笑奥地利,Milestone Medical,Neogenomics Laboratories，Inc。,PHC Holdings Corporation,Quest Diagnostics inclinated.,R. K. SCIENTIFIC INSTRUMENT PRIVATE LIMITED,Sakura Finetek,Sakura Finetek USA，Inc。,和Slee Medical GmbH |
